http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Igawa, Satoshi,Sato, Yuichi,Ishihara, Mikiko,Kasajima, Masashi,Kusuhara, Seiichiro,Nakahara, Yoshiro,Otani, Sakiko,Fukui, Tomoya,Katagiri, Masato,Sasaki, Jiichiro,Masuda, Noriyuki Asian Pacific Journal of Cancer Prevention 2016 Asian Pacific journal of cancer prevention Vol.17 No.7
Background: Pemetrexed monotherapy has come to be recognized as one of the standard second-line therapies for advanced non-squamous non-small cell lung cancer (NSCLC). However, there have been no reports of studies that have evaluated the efficacy of pemetrexed according to type of active EGFR mutation, i.e., an exon 19 deletion or an L858R point mutation. Materials and Methods: The records of non-squamous NSCLC patients harboring an EGFR mutation who received pemetrexed monotherapy as a second or later line of chemotherapy at Kitasato University Hospital between March 2010 and October 2015 were retrospectively reviewed, and the treatment outcomes were evaluated. Results: The overall response rate and progression-free survival time (PFS) of the 53 patients with non-squamous NSCLC were 15.1% and 2.3 months, respectively. There were significant differences between the disease control rate (37.5% vs. 76.2%) and PFS time (1.8 months vs. 3.3 months) of the exon 19 deletion group and the L858R point mutation group, and a multivariate analysis identified type of EGFR mutation as well as performance status (PS) as independent predictors of PFS. Conclusions: The clinical data obtained in this study provided a valuable rationale for considering type of EGFR mutation as well as non-squamous histology as predictors of the efficacy of pemetrexed monotherapy.
Beta3-Adrenoceptor Agonists: Possible Role in the Treatment of Overactive Bladder
Yasuhiko Igawa,Naoki Aizawa,Yukio Homma 대한비뇨의학회 2010 Investigative and Clinical Urology Vol.51 No.12
In the present review article, we present an overview of beta-adrenoceptor (b-AR) subtype expression at the mRNA and receptor protein levels in the human detrusor, the in vitro and in vivo bladder function of the b3-AR, the in vivo effect of b3-AR agonists on detrusor overactivity in animal models, and the available results of clinical trials of b3-AR agonists for treating overactive bladder (OAB). There is a predominant expression of b3-AR mRNA in human bladder, constituting 97% of total b-AR mRNA. Also, functionally, the relaxant response of human detrusor to catecholamines is mainly mediated through the b3-ARs. Moreover, the presence of b1-, b2-, and b3-AR mRNAs in the urothelium and suburothelial layer of human bladder has been identified. Stimulation of urothelial b-ARs results in the release of nitric oxide and an unknown substance inhibiting detrusor contractions from the urothelium. Intravenous application of CL316,243, a selective b3-AR agonist, in rats selectively inhibits mechano-sensitive Ad-fiber activity of the primary bladder afferents. A number of selective b3-AR agonists are currently being evaluated in clinical trials for OAB with promising preliminary results. In conclusion, the b3-AR agonists are the most notable alternative class of agents to antimuscarinics in the pharmacological treatment of OAB. The b3-AR agonists act to facilitate bladder storage function probably through at least two mechanisms: first, direct inhibition of the detrusor, and second, inhibition of bladder afferent neurotransduction.
( Tae Woong Oh ),( Shoji Igawa ),( Tatsuki Naka ) 한국운동영양학회 2015 Physical Activity and Nutrition (Phys Act Nutr) Vol.19 No.3
[Purpose] we aim to examine whether adding exercise has impact on obesity prevention and bone metabolism in senior rats, to which dietary obesity was induced through skim milk intake. [Methods] We used 47, 14-week old Sprague -Dawley (SD) female rats (CLEA Japan, Inc.). The Rats were separated into four random groups: 1) a Non-Ex group with a normal diet (n = 12), 2) an Ex group with a normal diet (n = 12), 3) a Non-Ex group with a skim milk diet (n = 11), and 4) an Ex group with a skim milk diet (n = 12). As the exercise for each Ex group, rats ran on a treadmill starting at 27-week old (TREADMILL CONTROL LE8710 and TREADMILL CONTROL LE8700, Harvard Bioscience). Training protocol stipulated a frequency of five times a week for 12 weeks. [Results] The leptin concentration differed with dietary content: compared to the Ex group with a skim milk diet, Non-Ex and Ex groups with a normal diet showed significantly higher values (p < 0.05). The Ex group had significantly lower values in both the normal diet and skim milk diet groups with or without exercise (p < 0.05).Compared to the Non-Ex group with a normal diet, BS/BV (mm2/mm3), BV/TV (%), Tb.Th (μm), TBPf (/mm) and Tb.N (/mm) had significantly lower in the Ex group, the Ex and Non-Ex groups with a whey protein diet, and the Ex group with a skim milk protein diet (p < 0.05). [Conclusion] These findings suggest that senior female rats fed SMP would have higher bone structural and strength parameters than rats fed a normal diet.
Case Reports : Morphea on the Breast after a Needle Biopsy
( Noriko Arase ),( Ken Igawa ),( Satoko Senda ),( Mika Terao ),( Hiroyuki Murota ),( Ichiro Katayama ) 대한피부과학회 2011 Annals of Dermatology Vol.23 No.3s
Localized scleroderma (morphea) usually develops spontaneously, but the precise mechanisms underlying disease development are obscure. However, a significant number of cases suggest that morphea is induced by external stimuli. Herein, we report a case of morphea that developed after a needle biopsy. (Ann Dermatol 23(S3) S408~S410, 2011)
Morphea on the Breast after a Needle Biopsy
Noriko Arase,Ken Igawa,Satoko Senda,Mika Terao,Hiroyuki Murota,Ichiro Katayama 대한피부과학회 2011 Annals of Dermatology Vol.23 No.-
Localized scleroderma (morphea) usually develops spontaneously,but the precise mechanisms underlying disease development are obscure. However, a significant number of cases suggest that morphea is induced by external stimuli. Herein, we report a case of morphea that developed after a needle biopsy. (Ann Dermatol 23(S3) S408∼S410, 2011)